Immunoablation and autologous hematopoietic stem cell transplantation (AHSCT) in multiple sclerosis

Revue neurologique
A Créange, D Farge-Bancel

Abstract

Numerous pathophysiological arguments supporting immunosuppression for multiple sclerosis have been collected during recent years. The relevance of intense immunosuppression, in terms of clinical benefit and early or late risk, remains a matter of discussion. Immunoablation followed by autologous hematopoietic stem cell transplantation (AHSCT) in multiple sclerosis uses intense immunosuppression, followed by reinjection of AHSC, a rescue procedure for the induced aplasia. This method targets disappearance of the immune disorder, and thus, in theory, the interruption of the disease course. Use of AHSCT to treat several types of autoimmune diseases has been performed with contrasted results. In multiple sclerosis, the experience has been gained over the past 10 years through short series of patients treated at a late stage of their disease. This article highlights the recent data of this particular treatment option in multiple sclerosis as well as the therapeutic aims that should be investigated in further trials.

References

May 1, 1992·Neurology·A D SadovnickD W Paty
Dec 22, 1983·The New England Journal of Medicine·C I SmithG Matell
Dec 1, 1994·Pathology International·S Ikehara
Mar 11, 1998·Lancet·E F LampeterH Kolb
Nov 18, 2000·The New England Journal of Medicine·C ConfavreuxP Adeleine
Jun 19, 2001·Annals of the Rheumatic Diseases·A TyndallA Gratwohl
Jul 11, 2001·Neurology·G L MancardiUNKNOWN Italian GITMO-NEURO Intergroup on Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
Aug 27, 2002·Journal of Neurology·A FassasUNKNOWN Autoimmune Disease Working Party of the EBMT (European Group for Blood and Marrow Transplantation)
Nov 14, 2002·Proceedings of the National Academy of Sciences of the United States of America·Jonathan KipnisMichal Schwartz
May 4, 2004·Lupus·David JayneUNKNOWN European League Against Rheumatism Registry
Jul 14, 2004·Annals of the Rheumatic Diseases·D FargeUNKNOWN EBMT/EULAR Registry
Jan 22, 2005·Neurologic Clinics·Harold Atkins, Mark Freedman
Feb 24, 2005·Journal of Autoimmunity·Amy L PutnamPeter A Gottlieb
Oct 13, 2005·Brain : a Journal of Neurology·F FéronA Mackay-Sim
Nov 5, 2005·Acta Haematologica·Alan Tyndall, Thomas Daikeler
Jun 9, 2006·Nature Reviews. Neuroscience·Gianvito Martino, Stefano Pluchino
Feb 1, 2007·Multiple Sclerosis : Clinical and Laboratory Research·Neil Scolding
Feb 1, 2007·Multiple Sclerosis : Clinical and Laboratory Research·R SaccardiUNKNOWN Autoimmune Diseases Working Party of EBMT
Feb 1, 2007·Multiple Sclerosis : Clinical and Laboratory Research·S Martínez-YélamosTx Arbizu
Feb 15, 2007·The European Journal of Neuroscience·Karine MagalonPascale Durbec
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Brahim Nait-OumesmarAnne Baron-Van Evercooren
Jun 7, 2007·Brain : a Journal of Neurology·A WoodhooK R Jessen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.